Raffles Medical FY2025 PATMI SGD70.6 million +13.4%

Reuters
02/23
Raffles Medical FY2025 PATMI SGD70.6 million +13.4%

Raffles Medical reported FY2025 revenue of SGD 765.3 million (+1.8%) and profit attributable to shareholders of SGD 70.57 million (+13.4%). Profit before tax was SGD 93.59 million (+7.6%), while basic EPS was 3.81 cents (+13.7%). For 2H2025, revenue was SGD 386.85 million (+0.3%) and profit attributable to shareholders was SGD 38.46 million (+21.7%), with basic EPS of 2.08 cents (+22.4%). By segment in FY2025, Hospital Services revenue was SGD 357.82 million and segment profit before tax was SGD 41.13 million, while Healthcare Services revenue was SGD 285.90 million and segment profit before tax was SGD 42.49 million. Insurance Services revenue was SGD 185.23 million and segment profit before tax was a loss of SGD 3.12 million, and Investment Holdings revenue was SGD 44.31 million with segment profit before tax of SGD 27.16 million. The group cited a SGD 4.7 million fair value gain on investment properties as a key contributor to higher other operating income, and said lower insurance service expenses reflected improved claims experience despite FY2025 insurance revenue of SGD 179.12 million. Raffles Medical ended FY2025 with cash and cash equivalents of SGD 310.79 million, and generated SGD 101.33 million of net cash from operating activities. The board proposed a final dividend of 3.0 cents per share (one-tier tax), payable on 22 May 2026 subject to shareholder approval, with books closure on 14 May 2026. The group also said its physician-led Raffles Healthy Longevity Centre is scheduled to open in Q1 2026, and disclosed that a subsidiary completed the acquisition of the remaining 30% stake in Shanghai Qihua Hospital for SGD 16.6 million in October 2025.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Raffles Medical Group Ltd. published the original content used to generate this news brief via Singapore Exchange Limited (SGX) (Ref. ID: LIKN158BB8VBHOPN) on February 22, 2026, and is solely responsible for the information contained therein.

應版權方要求,你需要登入查看該內容

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10